Inactive Instrument

Highlights GEMI THER

Equities

GMTX

US36870G1058

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Arix portfolio firm Disc Medicine seals Gemini Therapeutics merger	22-12-30	AN
Disc Medicine, Inc. completed the acquisition of Gemini Therapeutics, Inc. for approximately $200 million in a reverse merger transaction.	22-12-28	CI
Gemini Therapeutics' Disc Medicine Secures FDA's Orphan Drug Status for Erythropoietic Protoporphyria Treatment	22-12-22	MT
Gemini Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
GEMINI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX	22-08-12	BU
Gemini Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Arix Bioscience To Invest $54 Million To Fund All-stock Disc Medicine, Gemini Therapeutics Merger	22-08-11	MT
Conference Call Transcript Gemini Therapeutics and Disc Medicine Merger Agreement Announcement August 10, 2022 / 08:00 AM ET - Form 8-K	22-08-10	PU
Gemini Therapeutics Merges With Disc Medicine	22-08-10	MT
Gemini Therapeutics, Inc. and Disc Medicine, Inc. Merger Agreement Call	22-08-10	FA
Gemini Therapeutics : and Disc Medicine Announce Merger Agreement - Form 8-K	22-08-10	PU
Gemini Therapeutics and Disc Medicine Announce Merger Agreement	22-08-10	BU
Disc Medicine, Inc. entered into an agreement to acquire Gemini Therapeutics, Inc. in a reverse merger transaction.	22-08-09	CI
Gemini Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-06	CI
Gemini Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-10	CI
Gemini Therapeutics, Inc. Announces Updates from Ongoing Phase 2A Clinical Studies of GEM103 and Strategic Evaluation of GEM103's Clinical Development Program	22-01-10	CI
Gemini Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Earnings Flash (GMTX) GEMINI THERAPEUTICS Posts Q3 Loss $-0.43	21-11-15	MT
Gemini Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended and Six Month Ended June 30, 2021	21-08-12	CI
Gemini Therapeutics Announces Initial Data from Its Ongoing Phase 2A Study of GEM103	21-06-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GEMI THER

Equities

GMTX

US36870G1058

Highlights

Filters